# Career Enhancement Program (CEP)

> **NIH NIH P50** · DANA-FARBER CANCER INST · 2022 · $86,947

## Abstract

Project Summary
CAREER ENHANCEMENT PROGRAM
THE OVERALL OBJECTIVE of the Career Advancement Program will be: to increase the breadth and depth of
the ovarian cancer translational investigator pool at the DF/HCC and across the US. We expect to train
individuals who will become 2025’s National / International leaders in the pathobiology, diagnosis, treatment
and control of Ovarian Cancers. The program will be led by Dr. David Spriggs, one of the overall SPORE PI’s
and with the ongoing advice and consultation of Drs D’Andrea and Dr. Steve Cannistra. Dr. Spriggs has a long
track record of successful recruiting and mentoring new academic investigators into new drug development
and ovarian cancer treatment. The Specific aims will define the Career Enhancement Program: Aim 1.
Identify appropriate candidates, primarily junior faculty members seeking to become independent investigators
in ovarian cancer research, provide and secure funding for these investigators, and assure SPORE resources
for awardees. This group will include applicants from the rich DFHCC pool of fellows and junior faculty as well
as candidates from the other New England Institutions, Collaborating SPORE’s and national candidates
solicited from AACR and the Society of Gynecologic Oncology. We are particularly committed to increase the
diversity of the peer reviewed translational science investigators in ovarian cancer. Selection will rely on the
entire SPORE leadership and be confirmed by the EAB. Aim 2. Promote a mentoring environment and plan
that will assist the career enhancement and success of the CEP awardees. Through the environment in the
DF/HCC, we will create individualized training programs (IDP’s)for every funded junior faculty person and build
a team of scientific, clinical and personal mentors around each one; Aim 3. Monitor the scientific and
academic progress of the awardees and the program. Particular attention will be given transition points, such
as the instructor/assistant professor interface and the attainment of RO1 equivalent funding which will mark
transition to full independence. Short term outcome measures will include publication of high impact papers
and the submission of extramural peer reviewed funding. Long term outcomes will be persistence in ovarian
cancer translational research as measured by continuing peer reviewed publication in ovarian cancer research
and achievement of senior faculty status at academic institutions 5-7 years after completion of the CEP
completion. The majority of support will come from a variety of institutional sources from the DFHCC, the
DFCI, the Beth Israel Deaconess Medical Center and the MGH. Specific plans for the identification, recruitment
and mentoring of a diverse awardee pool will incorporate resources for specific gender and minority
recruitment efforts from Harvard Medical School and the individual hospitals involved in the SPORE.

## Key facts

- **NIH application ID:** 10469379
- **Project number:** 5P50CA240243-03
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** Cesar M Castro
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $86,947
- **Award type:** 5
- **Project period:** 2020-08-03 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10469379

## Citation

> US National Institutes of Health, RePORTER application 10469379, Career Enhancement Program (CEP) (5P50CA240243-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10469379. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*